vs
EXACT SCIENCES CORP（EXAS）与Fortrea Holdings Inc.（FTRE）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Fortrea Holdings Inc.的1.3倍（$878.4M vs $660.5M）。Fortrea Holdings Inc.净利率更高（-4.9% vs -9.8%，领先4.9%）。EXACT SCIENCES CORP同比增速更快（23.1% vs -5.2%）。Fortrea Holdings Inc.自由现金流更多（$121.6M vs $120.4M）。过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs -0.1%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Fortrea Holdings Inc.是一家总部位于美国北卡罗来纳州达勒姆、注册地为特拉华州的合同研究组织，业务覆盖90个国家，主要服务制药、生物技术和医疗器械行业客户，为相关领域的研发提供专业支持。
EXAS vs FTRE — 直观对比
营收规模更大
EXAS
是对方的1.3倍
$660.5M
营收增速更快
EXAS
高出28.4%
-5.2%
净利率更高
FTRE
高出4.9%
-9.8%
自由现金流更多
FTRE
多$1.2M
$120.4M
两年增速更快
EXAS
近两年复合增速
-0.1%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $660.5M |
| 净利润 | $-86.0M | $-32.5M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | -2.1% |
| 净利率 | -9.8% | -4.9% |
| 营收同比 | 23.1% | -5.2% |
| 净利润同比 | 90.1% | 46.9% |
| 每股收益（稀释后） | $-0.45 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFTRE
| Q4 25 | $878.4M | $660.5M | ||
| Q3 25 | $850.7M | $701.3M | ||
| Q2 25 | $811.1M | $710.3M | ||
| Q1 25 | $706.8M | $651.3M | ||
| Q4 24 | $713.4M | $697.0M | ||
| Q3 24 | $708.7M | $674.9M | ||
| Q2 24 | $699.3M | $662.4M | ||
| Q1 24 | $637.5M | $662.1M |
净利润EXASFTRE
| Q4 25 | $-86.0M | $-32.5M | ||
| Q3 25 | $-19.6M | $-15.9M | ||
| Q2 25 | $-1.2M | $-374.9M | ||
| Q1 25 | $-101.2M | $-562.9M | ||
| Q4 24 | $-864.6M | $-61.2M | ||
| Q3 24 | $-38.2M | $-27.9M | ||
| Q2 24 | $-15.8M | $-138.4M | ||
| Q1 24 | $-110.2M | $-101.0M |
毛利率EXASFTRE
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFTRE
| Q4 25 | -9.4% | -2.1% | ||
| Q3 25 | -3.0% | -1.2% | ||
| Q2 25 | -0.3% | -46.5% | ||
| Q1 25 | -13.6% | -79.9% | ||
| Q4 24 | -122.8% | -8.0% | ||
| Q3 24 | -5.6% | -2.7% | ||
| Q2 24 | -3.8% | -7.7% | ||
| Q1 24 | -16.7% | -5.6% |
净利率EXASFTRE
| Q4 25 | -9.8% | -4.9% | ||
| Q3 25 | -2.3% | -2.3% | ||
| Q2 25 | -0.1% | -52.8% | ||
| Q1 25 | -14.3% | -86.4% | ||
| Q4 24 | -121.2% | -8.8% | ||
| Q3 24 | -5.4% | -4.1% | ||
| Q2 24 | -2.3% | -20.9% | ||
| Q1 24 | -17.3% | -15.3% |
每股收益（稀释后）EXASFTRE
| Q4 25 | $-0.45 | $-0.25 | ||
| Q3 25 | $-0.10 | $-0.17 | ||
| Q2 25 | $-0.01 | $-4.14 | ||
| Q1 25 | $-0.54 | $-6.25 | ||
| Q4 24 | $-4.69 | $-0.68 | ||
| Q3 24 | $-0.21 | $-0.31 | ||
| Q2 24 | $-0.09 | $-1.55 | ||
| Q1 24 | $-0.60 | $-1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $174.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $563.5M |
| 总资产 | $5.9B | $2.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASFTRE
| Q4 25 | $964.7M | $174.6M | ||
| Q3 25 | $1.0B | $131.3M | ||
| Q2 25 | $858.4M | $81.2M | ||
| Q1 25 | $786.2M | $101.6M | ||
| Q4 24 | $1.0B | $118.5M | ||
| Q3 24 | $1.0B | $105.3M | ||
| Q2 24 | $946.8M | $126.2M | ||
| Q1 24 | $652.1M | $92.8M |
股东权益EXASFTRE
| Q4 25 | $2.4B | $563.5M | ||
| Q3 25 | $2.5B | $580.8M | ||
| Q2 25 | $2.5B | $589.2M | ||
| Q1 25 | $2.4B | $858.8M | ||
| Q4 24 | $2.4B | $1.4B | ||
| Q3 24 | $3.2B | $1.5B | ||
| Q2 24 | $3.2B | $1.5B | ||
| Q1 24 | $3.1B | $1.6B |
总资产EXASFTRE
| Q4 25 | $5.9B | $2.7B | ||
| Q3 25 | $5.9B | $2.7B | ||
| Q2 25 | $5.8B | $2.8B | ||
| Q1 25 | $5.7B | $3.1B | ||
| Q4 24 | $5.9B | $3.6B | ||
| Q3 24 | $6.7B | $3.7B | ||
| Q2 24 | $6.7B | $3.6B | ||
| Q1 24 | $6.4B | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $129.1M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $121.6M |
| 自由现金流率自由现金流/营收 | 13.7% | 18.4% |
| 资本支出强度资本支出/营收 | 3.6% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | $88.3M |
8季度趋势，按日历期对齐
经营现金流EXASFTRE
| Q4 25 | $151.7M | $129.1M | ||
| Q3 25 | $219.9M | $86.8M | ||
| Q2 25 | $89.0M | $21.8M | ||
| Q1 25 | $30.8M | $-124.2M | ||
| Q4 24 | $47.1M | $17.1M | ||
| Q3 24 | $138.7M | $-2.4M | ||
| Q2 24 | $107.1M | $273.7M | ||
| Q1 24 | $-82.3M | $-25.6M |
自由现金流EXASFTRE
| Q4 25 | $120.4M | $121.6M | ||
| Q3 25 | $190.0M | $79.5M | ||
| Q2 25 | $46.7M | $14.3M | ||
| Q1 25 | $-365.0K | $-127.1M | ||
| Q4 24 | $10.7M | $13.9M | ||
| Q3 24 | $112.6M | $-10.6M | ||
| Q2 24 | $71.2M | $262.5M | ||
| Q1 24 | $-120.0M | $-34.9M |
自由现金流率EXASFTRE
| Q4 25 | 13.7% | 18.4% | ||
| Q3 25 | 22.3% | 11.3% | ||
| Q2 25 | 5.8% | 2.0% | ||
| Q1 25 | -0.1% | -19.5% | ||
| Q4 24 | 1.5% | 2.0% | ||
| Q3 24 | 15.9% | -1.6% | ||
| Q2 24 | 10.2% | 39.6% | ||
| Q1 24 | -18.8% | -5.3% |
资本支出强度EXASFTRE
| Q4 25 | 3.6% | 1.1% | ||
| Q3 25 | 3.5% | 1.0% | ||
| Q2 25 | 5.2% | 1.1% | ||
| Q1 25 | 4.4% | 0.4% | ||
| Q4 24 | 5.1% | 0.5% | ||
| Q3 24 | 3.7% | 1.2% | ||
| Q2 24 | 5.1% | 1.7% | ||
| Q1 24 | 5.9% | 1.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FTRE
暂无分部数据
